Resultados de la búsqueda 1-10 of 1272 for SC

  1. Ensayos clínicos - Hematología

    SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM. Jacksonville, Fla. The purpose of this study is to demonstrate the ...

  2. Hematología - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to demonstrate the efficacy non-inferiority between isatuximab SC and isatuximab IV in combination with pomalidomide and ...

  3. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  4. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  5. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  6. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  7. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  8. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  9. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  10. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...